Bispecific T-Cell Engager Clinical Translation Is Not Predicted by Target Antigen Density Alone: A Field-Level Empirical Analysis of Joint Binding–Effector Context

Bispecific T-cell engager (TCE) development continues to attract substantial industrial investment alongside a translation record that remains uneven across target antigens and disease settings. Multiple independent reports across the field have observed that target antigen density on tumor cells does not predict cytotoxic potency or clinical response, while other reports describe within-target density-potency correlations of widely varying strength. These findings, when read in parallel, appear contradictory and have not been organized by any unifying analytical framework that has gained adoption in the field's standard practice. A mechanistically motivated joint binding-effector framework suggested that this apparent contradiction may reflect a single biological structure being read through analytical conventions that examine target antigen density and effector-side biology in isolation. To investigate this systematically, we assembled a verified dataset of bispecific TCE clinical-stage programs spanning eleven target antigens (CD19, CD20, BCMA, GPRC5D, CD33, CD123, CLL-1, FLT3, EpCAM, PSMA, and DLL3) and read it against the published primary-source record of within-target density-outcome reports. The systematic empirical pattern that emerges is consistent with a joint binding-effector structure in which neither variable alone is sufficient. In the limiting case, target cells lacking the antigen produce no cytotoxicity at any effector-to-target ratio. The published record reflects the two variables asymmetrically by design: target antigen density is reported across cell-line panels, primary samples, and clinical correlative cohorts, while effector-side variation is structurally absent from cell-line panels (which fix effector-to-target ratios at non-biological values with uniform donor T cells) and is observable only in primary-sample and clinical correlative analyses. Across approved drug programs at clinical exposure, target antigen density does not predict outcome (verified in multiple peer-reviewed primary samples and clinical correlative analyses including a registration-trial cohort of n=165); in those same settings, measures of effector-side biology -- effector-to-target ratio, T-cell counts, regulatory T-cell frequency, and exhaustion markers -- are associated with outcome, consistent with the elementary requirement that both antigen-bearing targets and adequate effector cells are needed for TCE activity. Within-program triangulation in a discontinued clinical-development program (CD33/AMG 330) demonstrates the same structural pattern in the failure direction. We propose the joint binding-effector account as a testable explanation that reconciles the systematic empirical record assembled here: it is logically coherent, internally consistent, and consistent with the field's documented findings. The systematic dataset and the verified primary-source documentation are deposited as supplementary material to support independent evaluation.